Ho AM, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, Nassan M, Colby CL, Larrabee BR, Weinshilboum RM, Frye MA, Biernacka JM. Mood-stabilizing antiepileptic treatment response in bipolar disorder: a genome-wide Association study. Clin Pharmacol Ther. 2020;108(6):1233–42. https://doi.org/10.1002/cpt.1982.
Baena-Oquendo S, Valencia JG, Vargas C, López-Jaramillo C. Neuropsychological aspects of bipolar disorder. Rev Colomb Psiquiatr. 2021. https://doi.org/10.1016/j.rcp.2020.08.003. S0034-7450(20)30092-5.
Nikolitch K, Saraf G, Solmi M, Kroenke K, Fiedorowicz JG. Fire and darkness: on the Assessment and Management of Bipolar Disorder. Med Clin North Am. 2023;107(1):31–60. https://doi.org/10.1016/j.mcna.2022.04.002.
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–50. https://doi.org/10.1016/S2215-0366(21)00395-3.
McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, Malhi GS, Nierenberg AA, Rosenblat JD, Majeed A, Vieta E, Vinberg M, Young AH, Mansur RB. Bipolar disorders. Lancet. 2020;396(10265):1841–56. https://doi.org/10.1016/S0140-6736(20)31544-0.
He H, Hu C, Ren Z, Bai L, Gao F, Lyu J. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: results from the global burden of Disease Study 2017. J Psychiatr Res. 2020;125:96–105. https://doi.org/10.1016/j.jpsychires.2020.03.015.
de Filippis R, Menculini G, D’Angelo M, Carbone EA, Tortorella A, De Fazio P, Steardo L Jr. Internalized-stigma and dissociative experiences in bipolar disorder. Front Psychiatry. 2022;13:953621. https://doi.org/10.3389/fpsyt.2022.953621.
Dimick MK, Hird MA, Sultan AA, Mitchell RHB, Sinyor M, MacIntosh BJ, Goldstein BI. Resting-state functional connectivity indicators of risk and resilience for self-harm in adolescent bipolar disorder. Psychol Med. 2023;53(8):3377–86. https://doi.org/10.1017/S0033291721005419.
Chen CK, Yang SY, Park SC, Jang OJ, Zhu X, Xiang YT, Ouyang WC, Javed A, Khan MNS, Grover S, Avasthi A, Kallivayalil RA, Chee KY, Chemi N, Kato TA, Hayakawa K, Pariwatcharakul P, Maramis M, Seneviratne L, Sim K, Tang WK, Oo T, Sartorius N, Tan CH, Chong MY, Park YC, Shinfuku N, Lin SK. Clinical use of mood stabilizers beyond treatment for bipolar disorder: the REAP-MS study. Asian J Psychiatr. 2023;85:103613. https://doi.org/10.1016/j.ajp.2023.103613.
Rybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord. 2018;20(4):391–92. https://doi.org/10.1111/bdi.12608.
Suran M. Treating bipolar disorder is notoriously difficult, but Research Underway could lead to New options. JAMA. 2023. https://doi.org/10.1001/jama.2023.10057.
Rybakowski JK. Mood stabilizers of First and Second Generation. Brain Sci. 2023;13(5):741. https://doi.org/10.3390/brainsci13050741.
Singh B, Yocum AK, Strawbridge R, Burdick KE, Millett CE, Peters AT, Sperry SH, Fico G, Vieta E, Verdolini N, Godin O, Leboyer M, Etain B, Tso IF, Coombes BJ, McInnis MG, Nierenberg AA, Young AH, Ashton MM, Berk M, Williams LJ, Keramatian K, Yatham LN, Overs BJ, Fullerton JM, Roberts G, Mitchell PB, Andreassen OA, Andreazza AC, Zandi PP, Pham D, Biernacka JM, Frye MA. FACE-BD collaborators, The Global Bipolar Cohort Collaborative. Patterns of pharmacotherapy for bipolar disorder: a GBC survey. Bipolar Disord. 2023. https://doi.org/10.1111/bdi.13366.
Tarzian M, Soudan M, Alhajji M, Ndrio M, Fakoya AO. Lurasidone for treating Schizophrenia and Bipolar Depression: a review of its efficacy. Cureus. 2023;15(4):e38071. https://doi.org/10.7759/cureus.38071.
Belmaker RH. Lurasidone and bipolar disorder. Am J Psychiatry. 2014;171(2):131–33. https://doi.org/10.1176/appi.ajp.2013.13091240.
Chen J. Yi Ru Fang. A novel atypical antipsychotic: Lurasidone. J Clin Psychol Med. 2022;32(1):81. https://doi.org/10.3969/j.issn.1005-3220.2022.01.024
Azhar Y, Shaban K. Lurasidone. In: StatPearls. 2023. PMID: 31082101.
Fiorillo A, Cuomo A, Sampogna G, Albert U, Calò P, Cerveri G, De Filippis S, Masi G, Pompili M, Serafini G, Vita A, Zuddas A, Fagiolini A. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert Opin Pharmacother. 2022;23(16):1801–18. https://doi.org/10.1080/14656566.2022.2141568
Takaesu Y, Takeshima M, Watanabe K. Effectiveness and tolerability of Lurasidone for bipolar types I and II and other specified bipolar depression: a 12-Week observational study. J Clin Psychopharmacol. 2022;42(5):485–88. https://doi.org/10.1097/JCP.0000000000001590
Kato M, Masuda T, Sano F, Kato T. The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: a pooled post-hoc analysis of two randomized, placebo-controlled trials. J Affect Disord. 2023;337:150–58. https://doi.org/10.1016/j.jad.2023.05.065
Goldberg JF, Siu C, Tocco M, Pikalov A, Loebel A. The effect of Lurasidone on anxiety symptoms in patients with bipolar depression: a Post Hoc Analysis. J Clin Psychiatry. 2023;84(4):22m14732. https://doi.org/10.4088/JCP.22m14732
Ricci V, Di Salvo G, Maina G. Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report. Int Clin Psychopharmacol. 2023;38(4):275–80. https://doi.org/10.1097/YIC.0000000000000465
Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17(1):373. https://doi.org/10.1186/s12888-017-1539-0
Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897–904. https://doi.org/10.1002/j.1552-4604
Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27. https://doi.org/10.1016/j.jad.2013.10.040
Shang X, Guo W, Zhu ZY, Zhou JQ, Liu W, Cao MJ, Yao SY. Data analysis of adverse events signals for lurasidone based on FAERS database. Practical Pharm Clin Remedies. 2023;26(4):311–16. https://doi.org/10.14053/j.cnki.ppcr.202304005.
Hafeez ZH. Exanthematous Rash with Lurasidone in an Elderly Woman with Schizoaffective Disorder. Prim Care Companion CNS Disord. 2019;21(2):18l02370. https://doi.org/10.4088/PCC.18l02370
Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007;572(2–3):160–70. https://doi.org/10.1016/j.ejphar.2007.06.058
Haizhen Zhong. Skin rash caused by piropilone: a case report. J Psychiatry. 2014;27(4):287. https://doi.org/10.3969/j.issn.1009-7201.2014.04.016
Cao Y, Bairam A, Liu MC, Uetrecht J. Potential involvement of sulfotransferase in the mechanism of Lamotrigine-induced skin Rash. Chem Res Toxicol. 2023;36(11):1711–16. https://doi.org/10.1021/acs.chemrestox.3c00187
Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21–37. https://doi.org/10.2165/00002018-200831010-00003
Bryant CA, Cinibulk M, Manchee C, Cho SH. Running out of options: a case of DRESS with possible neosensitization to Lurasidone in an acutely Manic, psychotic, and Catatonic Patient. J Acad Consult Liaison Psychiatry. 2022;63:S180–1. https://doi.org/10.1016/j.jaclp.2022.10.140
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97. https://doi.org/10.1016/j.amjmed.2011.01.017
Swati C, Singh H, Bunty S. Case report of olanzapine induced psoriasis in a young adult male with Acute transient psychotic disorder. Indian J Psychiatry. 2022;64(SUPPL 3):S613–4.
